ClinicalTrials.gg
CompletedNCT03315039Updated Mar 10, 2022Results posted

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

A Phase 1/2 interventional study of Liposomal Annamycin in Leukemia, Myeloid, Acute, sponsored by Moleculin Biotech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-10.

Sponsored by Moleculin Biotech, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,674th of 1,907
7 · median 35
Started
2018
with 98 others
Phase 1/2
306 of 2,137
47 open now
Registered
1,412th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,674th largest by enrollment of the 1,907 interventional ones that give a count, is one of 99 that started in 2018, is one of 306 in phase 1/2, and was the 1,412th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy

03

Conditions studied

  • Leukemia, Myeloid, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A confirmed diagnosis of AML by World Health Organization (WHO) classification.
  2. AML that is to or relapsed after standard induction therapy.
  3. Age ≥18 years at the time of signing .
  4. No chemotherapy, radiation, or major surgery within two weeks prior to first dose of study drug and/or recovered from the toxic side effects of that therapy, unless treatment is indicated due to progressive disease.
  5. No therapy within four weeks of the first dose of study drug.
  6. (ECOG) performance status 0 to 2.
  7. Adequate laboratory results including the following:

    1. ≤1.5 times the (ULN) unless due to Gilbert Syndrome
    2. Serum glutamic-oxaloacetic transaminase (), serum glutamic-pyruvic transaminase (SGPT) and alkaline phosphatase \<3 times the ULN) unless due to organ involvement
    3. Adequate renal function (The equation will be used to estimate creatinine clearance. This equation is as follows: Creatinine clearance in ml/min = (140 - age) x body weight (kg)/72 x plasma creatinine (mg/dL); multiplied by 0.85 for women. Using this equation, adequate renal function will be deemed to be a creatinine clearance of greater than 60 ml/minute.)
  8. Prior anthracycline cumulative dose below 551 mg/m2 or the daunorubicin equivalent which is the recommended non-cardiotoxic level.
  9. Subject can understand and sign the informed consent document, can communicate with the investigator, and can understand and comply with the requirements of the protocol.
  10. Women of must have a negative serum or urine pregnancy test.
  11. All men and women must agree to practice effective during the entire study period and after discontinuing study drug, unless documentation of infertility exists.

    1. Sexually active, fertile women must use two effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least 6 months after discontinuing study drug
    2. Sexually active men and their sexual partners must use effective contraceptive methods from the time of subject informed consent and until at least 3 months after discontinuing study drug

Exclusion criteria

Exclusion Criteria:

  1. Subjects diagnosed with Acute Promyelocytic Leukemia.
  2. Concomitant therapy that includes other chemotherapy that is or may be active against AML except for prophylaxis and/or treatment of opportunistic or other infection with antibiotics, antifungals and/or antiviral agents.
  3. Prior mediastinal radiotherapy
  4. Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.
  5. Positive risk assessment for cardiovascular disease including prior anthracycline cumulative dose more than 50% above recommended non-cardiotoxic levels, (LVEF) \<50%, valvular heart disease, or severe hypertension, (see Table 1). Cardiac subjects with a (NYHA) classification of 3 or 4 will be excluded. (Cardiology consultation should be requested if any question arises about cardiac function.) This also includes subjects with baseline /QTc interval >480 msec, a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) and using concomitant medications that significantly prolong the QT/QTc interval.
  6. serious co-morbid medical conditions including, but not limited to, active infection, recent (less than or equal to six months) myocardial infarction, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, active CNS disease uncontrolled by standard of care, known positive status for (HIV) and/or active or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Pregnant, lactating, or not using adequate .
  8. Known allergy to anthracyclines.
  9. Any evidence of mucositis/stomatitis or previous history of severe (≥Grade 3) mucositis from prior therapy.
  10. Required use of strong inhibitors and inducers of CYP enzymes and transporters.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Liposomal annamycin

    2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).

    Drug: Liposomal Annamycin

Interventions

  • 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity

    Number of patients with a dose-limiting toxicity (DLT) at each dose evaluated

    Time frame: Day 28

Secondary outcomes

  1. Pharmacokinetics - Area Under the Plasma Concentration

    Area under the plasma concentration - time curve (AUC) of annamycin and its metabolite, annamycinol

    Time frame: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after the start of liposomal annamycin infusion on Day 1 and Day 3

  2. Number of Participants With Anti-leukemic Activity

    Determined by acute myeloid leukemia (AML) response rate based on the International Working Group (IWG) Response Criteria in AML (Cheson, 2003). Anti-leukemic Activity measured by bone marrow biopsy/aspirate pre and post treatment.

    Time frame: 15-35 Days after the start of therapy

07

Results

Posted Feb 23, 2022

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal Annamycin
Started43
Completed43
Not completed00

Outcome measures

PrimaryDose-limiting Toxicity

Number of patients with a dose-limiting toxicity (DLT) at each dose evaluated

Time frame:
Day 28
Reported as:
Count of participants · Participants
Dose-limiting Toxicity
ParticipantsDose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2 : 120 mg/m2/Day Liposomal Annamycin
Dose-limiting Toxicity00
SecondaryPharmacokinetics - Area Under the Plasma Concentration

Area under the plasma concentration - time curve (AUC) of annamycin and its metabolite, annamycinol

Time frame:
Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after the start of liposomal annamycin infusion on Day 1 and Day 3
Reported as:
Geometric mean · hr*ng/ml
Pharmacokinetics - Area Under the Plasma Concentration
hr*ng/mlLiposomal Annamycin
Annamycin 100 mg/m2 - Day 11430 ± 19.6
Annamycin 100 mg/m2 - Day 31610 ± 22.4
Annamycin 120 mg/m2 - Day 12330 ± 42.0
Annamycin 120 mg/m2 - Day 32880 ± 33.3
Annamycinol 100 mg/m2 - Day 11400 ± 43.9
Annamycinol 100 mg/m2 - Day 31520 ± 36.7
Annamycinol 120 mg/m2 - Day 11370 ± 39.5
Annamycinol 120 mg/m2 - Day 31610 ± 67.7
SecondaryNumber of Participants With Anti-leukemic Activity

Determined by acute myeloid leukemia (AML) response rate based on the International Working Group (IWG) Response Criteria in AML (Cheson, 2003). Anti-leukemic Activity measured by bone marrow biopsy/aspirate pre and post treatment.

Time frame:
15-35 Days after the start of therapy
Reported as:
Count of participants · Participants
Number of Participants With Anti-leukemic Activity
Participants100 mg/m2120 mg/m2
Morphological Leukemia Free State (MLFS)01
Treatment Failure (TF)42

Adverse events

Collected over 39 days after the last dose of study treatment, a total of about 1 year and 10 months since the start of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 mg/m2 Dose Level0/4 (0%)2/4 (50%)4/4 (100%)
120 mg/m2 Dose Level0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
Event100 mg/m2 Dose Level120 mg/m2 Dose Level
Flank PainGeneral disorders1/40/3
Respiratory FailureRespiratory, thoracic and mediastinal disorders1/40/3
Most frequent other events
Showing 10 of 69
Most frequent other events
Event100 mg/m2 Dose Level120 mg/m2 Dose Level
EpistaxisRespiratory, thoracic and mediastinal disorders0/43/3
DyspnoeaRespiratory, thoracic and mediastinal disorders3/41/3
HypokalaemiaMetabolism and nutrition disorders1/42/3
DiarrhoeaGastrointestinal disorders2/41/3
Platelet count decreasedInvestigations2/41/3
InsomniaPsychiatric disorders2/41/3
White blood cell count decreasedInvestigations2/41/3
HypomagnesaemiaMetabolism and nutrition disorders2/40/3
FatigueGeneral disorders2/40/3
FolliculitisInfections and infestations2/40/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal AnnamycinTotal
<=18 years000
Between 18 and 65 years112
>=65 years325
Age, Continuous
Age, Continuous(years)Dose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal AnnamycinTotal
Mean67.0 ± 6.7357.0 ± 18.1962.7 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal AnnamycinTotal
Female112
Male325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal AnnamycinTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White426
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Dose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal AnnamycinTotal
United States437
ECOG Performance Status
ECOG Performance Status(Participants)Dose Level 1: 100 mg/m2/Day Liposomal AnnamycinDose Level 2: 120 mg/m2/Day Liposomal AnnamycinTotal
ECOG - 0011
ECOG - 1314
ECOG- 2112
08

Study locations

4 sites
  • UC San Diego Health
    La Jolla, California 92093, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Southwest Cancer Center
    Lubbock, Texas 79415, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jan 2020, 21 months.

Results were first posted in Feb 2022, 2 years 1 month after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 21 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2017
First posted
Oct 19, 2017
StartActual
Mar 28, 2018
Primary completionActual
Jan 14, 2020
CompletionActual
Jun 20, 2020
Results first posted
Feb 23, 2022
Last update
Mar 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03315039
Lead sponsor
Moleculin Biotech, Inc.
Responsible party
Sponsor
First posted
Oct 19, 2017
Start date
Mar 28, 2018
Primary completion
Jan 14, 2020
Completion
Jun 20, 2020
Results posted
Feb 23, 2022
Last update
Mar 10, 2022

Study contacts

Robert Shepard, MD
study director · Moleculin Biotech, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Annamycin

Start the discussion